` ADVM (Adverum Biotechnologies Inc) vs S&P 500 Comparison - Alpha Spread

ADVM
vs
S&P 500

Over the past 12 months, ADVM has underperformed S&P 500, delivering a return of -61% compared to the S&P 500's +15% growth.

Stocks Performance
ADVM vs S&P 500

Loading
ADVM
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ADVM vs S&P 500

Loading
ADVM
S&P 500
Difference
www.alphaspread.com

Performance By Year
ADVM vs S&P 500

Loading
ADVM
S&P 500
Add Stock

Competitors Performance
Adverum Biotechnologies Inc vs Peers

S&P 500
ADVM
ABBV
AMGN
GILD
VRTX
Add Stock

Adverum Biotechnologies Inc
Glance View

Market Cap
59.6m USD
Industry
Biotechnology

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2014-07-31. The firm develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The firm's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

ADVM Intrinsic Value
0.16 USD
Overvaluation 94%
Intrinsic Value
Price
Back to Top